Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1glp-1 receptor agonistssubstance use disorderpsychiatry

Biological Psychiatry review examines GLP-1 agonists in mental and substance use disorders

McIntyre, Hendershot, Jerlhag and colleagues set out mechanistic models and potential targets for the drug class beyond metabolic indications.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 17 21:51 ETSource: Biological psychiatry

The wire

  1. 01Biological Psychiatry is publishing a review, dated Oct. 15, on GLP-1 receptor agonists as a lens on mechanisms and targets in treating and preventing mental and substance use disorders.
  2. 02Clinicians fielding questions about incretin use in addiction and psychiatric populations will want a citable synthesis of the mechanistic case.
  3. 03Only the title and authorship are available; this is a review rather than new trial data, so it generates no efficacy evidence of its own.

From the source

GLP-1 Receptor Agonists: Informing Mechanistic Models and Innovative Targets in the Treatment and Prevention of Mental and Substance Use Disorders

Biological psychiatry · 2026 Oct 15 · McIntyre RS, Hendershot CS, Jerlhag E et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42749380/